Inari Medical, Inc. (NARI) Reports Prelim Q4 Revenue of $82.3M-$83.3M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/11/2026
- Wall St bounces as oil cools, inflation risks keeps Fed in focus
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but on track for sharp weekly gain on supply concerns; US diesel hits record high
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Inari Medical Reports Preliminary Fourth Quarter 2021 Revenue
January 10, 2022 4:01 PM ESTIRVINE, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Inari Medical, Inc. (NASDAQ: NARI) (Inari), a medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today reported preliminary unaudited fourth quarter 2021 revenue.
Preliminary Fourth Quarter Highlights:
Preliminary unaudited revenue is expected to be between $82.8 and $83.3 million for the fourth quarter of 2021, up 14% sequentially and 71% year-over-year (at the midpoint of the range).Preliminary unaudited revenue for the full year 2021 is expected to be between $276.6 and $277.1... More